Trine Jakobi Nøttrup, MD, PhD, on BRCA Wild-Type Recurrent Ovarian Cancer: Novel Triplet Maintenance Regimen
ESMO Congress 2026
Trine Jakobi Nøttrup, MD, PhD, of Rigshospitalet, describes findings from the DOVACC trial, which evaluated the combination of olaparib, durvalumab, and UV1—a therapeutic cancer vaccine directed against human telomerase reverse transcriptase—as maintenance therapy in patients with BRCA wild-type recurrent ovarian cancer (Abstract LBA39).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract LBA77).
Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, presents findings from the prespecified first interim analysis of the phase III G-HOPE 001 trial, which showed that arcotatug tavatecan, a CLDN18.2-targeted antibody-drug conjugate, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with a manageable safety profile vs treatment of physician’s choice for patients with CLDN18.2-positive gastric or gastroesophageal junction (GEJ) cancer in the third-line and beyond setting (Abstract LBA77).
The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At the ESMO Congress 2026, invited discussant James J. Harding, MD, reviewed the results from the preplanned interim analysis (Abstract LBA8).
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy after at least one prior therapy for gastroesophageal cancer expressing CLDN18.2 in ≥ 25% tumor cells with membranous staining at any intensity (Abstract LBA7).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract 2875O).
